Back to search

University of Ioannina

Νευροφαρμακολογική μελέτη του εξωπυραμιδικού συστήματος

Abstract

dc:description

Introduction: Levodopa is the gold standard for treatment of Parkinsons Disease (PD). It's long-term use is obscured by the induction of motor response complications (Levodopa Induced Dyskinesia - LID) affecting the quality of life of the patients in a way that competes the disease itself. To date, there is no clear evidence as to which is the optimal way to administer Levodopa in respect to delaying or reduce the severity of LID. Purpose: aim of this study is to answer the following questions: 1. Which is the optimal way to administer Levodopa in respect to delaying or reduce the severity of LID? 2. Is LID inevitable? 3. Which is the relation between the total amount of Levodopa given at a specific time and also between the daily dose and LID? Methods: the 6-OHDA hemiparkinsonian rat model of PD was used in this study, in which rats exhibit every aspect of LID. In a first phase of the study we evaluated if the rotational behavior express the antiparkinsonian response to levodopa or it is part of LID. For these purposes rats divided into three groups. Group 1 received 1 X 6,25 mg/Kg, group 2 received 4 X 6,25mg/Kg and group 3 received 1 X 25 mg/Kg Levodopa for at least 10 days, while various dosage modifications where used in the following days. Results: The results of the evaluation of rotational behavior resulted in that it is mainly an aspect of LID rather than antiparkinsonian response. Group1 did not demonstrated any motor behavior for the first 12,5 ±2.5 days while when dyskinesias appeared they were significantly milder compared to any other treatment group. This group was also protected against LID when higher doses of levodopa were used. Group receiving the high levodopa dose (1 x 25 mg/Kg) demonstrated the highest scores of LID from the first day of treatment. Fragmenting this dose (4 x 6,25mg/Kg) in group 2, resulted milder scores of LID compared to group 3. The same cumulative dose of levodopa for the first 10 days of treatment between groups 2 and 3, resulted different amounts of LID, with the group 3 demonstrating significantly higher LID scores. Conclusions: in view of developing LID more important is the way administering levodopa (as supported by the continuous dopaminergic stimulation concept) but also the intensity of the dopaminergic stimulation (as it is expressed through the amount of every single dose) as it was demonstrated by this study. In the early stages of the disease starting levodopa in small fragmented through the day doses, seems to be the best practice in order to delay the appearance and to reduce the amount of LID. Also, as it was demonstrated in the present study, if LID is established, it cannot be reversed.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsironis, Christos
  • Τσιρώνης, Χρήστος

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/48895

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsironis, Christos; Τσιρώνης, Χρήστος. Νευροφαρμακολογική μελέτη του εξωπυραμιδικού συστήματος. University of Ioannina, 2020. http://hdl.handle.net/10442/hedi/48895